A New Milestone: 25% Human Albumin Injection Approved in China — A Breakthrough in Critical Care
At Dengyuemed, we closely follow breakthroughs in essential therapeutics and innovative drug developments.
Dengyue is excited to share that China has just taken an important step forward in critical care support therapy.
Recently, 25% High-Concentration Human Albumin Injection, independently developed by Shuyang Bio-Sciences (Chengdu), a subsidiary of Yuanda Life Science Group, has officially been approved for marketing by the National Medical Products Administration (NMPA).
This approval fills a major domestic gap in the availability of high-concentration albumin and offers new options for treating critically ill patients.
Why Is Human Albumin Injection a Big Deal?
✅ Powerful Volume Expansion & Hemodynamic Stability
With 4–5 times the colloid osmotic pressure of standard solutions, this 25% albumin product rapidly expands blood volume, supports hemodynamic stability, and stays intravascular for over 16 hours, outperforming crystalloid solutions.
✅ Effective Dehydration & Edema Relief
The high oncotic pressure—up to 5x that of normal plasma—reduces interstitial fluid accumulation, making it a valuable adjunct for treating brain edema, cirrhotic ascites, and nephrotic syndrome.
✅ Rapid Correction of Hypoalbuminemia
Human Albumin Injection offers a more efficient increase in serum albumin levels, especially for patients recovering from liver cancer surgery or suffering from severe infections, helping to improve clinical outcomes.
✅ Reduced Fluid Burden & Safer Resuscitation
In patients requiring large-volume fluid resuscitation (e.g., acute lung injury), high-concentration albumin significantly lowers total fluid volume, prevents fluid overload, and enhances treatment safety.
This newly approved 25% Human Albumin Injection not only broadens the clinical toolbox for managing critical illness in China but also marks a significant advancement in domestic plasma product innovation.
HongKong DengYue Medicine will continue to spotlight companies like Yuanda Shuyang that are driving progress in clinical therapeutics.
Dengyue welcome global partners interested in product registration, international distribution, or strategic collaboration to connect with us.
